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ABSTRACT
Anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) is characterized according to its various
manifestations, which include ectodermal dysplasia, vascular anomalies, osteopetrosis, and diverse immu-
nological abnormalities such as susceptibility to pathogens, impaired antibody responses to polysaccharides,
hypogammaglobulinemia, hyper-IgM syndrome, impaired natural killer cell cytotoxicity, and autoimmune dis-
eases. Two genes responsible for EDA-ID have been identified: nuclear factor-κB (NF-κB) essential modula-
tor (NEMO) for X-linked EDA-ID (XL-EDA-ID) and IκBα for autosomal-dominant EDA-ID (AD-EDA-ID). Both
genes are involved in NF-κB activation, such that mutations or related defects cause impaired NF-κB signaling.
In particular, NEMO mutations are scattered across the entire NEMO gene in XL-EDA-ID patients, which ex-
plains the broad spectrum of clinical manifestations and the difficulties associated with making a diagnosis. In
this review, we focus on the pathophysiology of EDA-ID and different diagnostic strategies, which will be bene-
ficial for early diagnosis and appropriate treatment.
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INTRODUCTION
Anhidrotic ectodermal dysplasia with immunodefi-
ciency (EDA-ID) is a primary immunodeficiency dis-
order in which patients present with various manifes-
tations, such as EDA, vascular anomalies, and os-
teopetrosis.1-5 The immunological features of EDA-ID
include susceptibility to pathogens, impaired anti-
body response to polysaccharrides, hypogamma-
globulinemia, hyper IgM syndrome, impaired natural
killer (NK) cell cytotoxicity, and autoimmune dis-
eases.6 Two genes responsible for EDA-ID have been
identified: nuclear factor-κB (NF-κB) essential modu-
lator (NEMO) in X-linked EDA-ID (XL-EDA-ID) and
IκBα in autosomal-dominant EDA-ID (AD-EDA-ID).
Both genes are involved in NF-κB activation such
that mutations or related defects cause impaired NF-
κB signalling.5,7 For the appropriate diagnosis and
treatment of EDA-ID, the physicians should be well
aware of the broad spectrum of its clinical pheno-
types. Moreover, in the genetic diagnosis of XL-EDA-
ID, the potential presence of a NEMO pseudogene
and the occurrence of somatic mosaicism must be
considered. In this review, we focus on the variable
clinical manifestations of XL-EDA-ID and the diagnos-
tic precautions that can be taken in individuals at risk
for the disease.
ETIOLOGY OF EDA-ID
The first case of EDA-ID, in a boy who died of miliary
tuberculosis, was reported by Frix et al. in 1986.8 The
second case involved a boy who suffered from multi-
ple life-threatening infections caused by Pseudomonas
aeruginosa, Mycobacterium avium, and cytomegalovi-
rus infections.3 In spite of extensive searches for the
cause of the refractory infections in these patients,
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Fig.　1　NF-κB activation pathways associated with NEMO and IκBα. The major molecules 
involved in the TLR-4, TNFR, CD40, and TCR signalling pathways and NEMO-mediated 
NF-κB activation are depicted. TOLLIP, Toll-interacting protein; MyD, myeloid differentia-
tion factor; IRAK, interleukin-1 receptor-associated kinase; TRAF, tumor necrosis factor re-
ceptor-associated factor; TRADD, tumor necrosis factor receptor-associated death domain; 
FADD, fas-associated protein with death domain; RIP, receptor-interacting protein; 
CARMA, caspase recruitment domain-containing membrane-associated guanylate kinase 
protein; BCL, B-cell lymphoma protein; MALT, mucosa-associated lymphoid tissue lympho-
ma translocation protein; Ub, poly-ubiquitin chain; P, phosphate.
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immunological dysfunctions were not identified. In
1996, Abinun et al. described a young male patient
with EDA-ID who had an impaired antibody response
to polysaccharide antigens.2 Their report was the first
to shed light on the mechanism of EDA-ID-associated
immunodeficiency. In 2001, three groups were able
to show that defects in the NEMO gene are responsi-
ble for XL-EDA-ID. Those authors demonstrated that
the clinical manifestations of XL-EDA-ID, including
EDA and the immunological dysfunctions, were
caused by impaired NF-κB activation due to the iden-
tified genetic alterations.5,9,10 In addition, in a 2003 pa-
per by Courtois et al., the etiology of AD-EDA-ID was
determined to be a heterozygous gain-of-function mu-
tation in the IκBα gene.7 As both forms of EDA-ID
are typically diagnosed by genetic testing, NEMO
and IκBα mutations have been linked to a broad
spectrum of clinical phenotypes.11 Currently, the esti-
mated incidence of XL-EDA-ID is 1 : 250,000 live male
births.6 In AD-EDA-ID, six patients and four IκBα
mutations have been reported thus far.7,12-15
THE ROLES OF NEMO AND IκBα IN THE
NF-κB ACTIVATION PATHWAY
NF-κB transcription factors are critical regulators of
immunity, the stress response, apoptosis, and differ-
entiation. Mammalian cells make use of two main NF-
κB activation pathways, the canonical pathway and
the non-canonical pathway. The canonical pathway, in
which NEMO and inhibitors of NF-κB (IκB) are es-
sential control elements, is induced by most physi-
ological NF-κB stimuli.16 NEMO and IκB are also in-
volved in the non-canonical NF-κB activation path-
way, albeit indirectly.17 Homo- or heterodimers of
NF-κB proteins (p50, p52, RelB, and c-rel) are nor-
mally retained in the cytoplasm through interactions
Manifestations and Mutations in EDA-ID
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Fig.　2　Schematic representations of the normal NEMO and IκBα genes. (A) The normal NEMO gene and a NEMO pseudo-
gene. Schematic representation of the coding-region domain and reported mutations in NEMO (B) and IκBα (C).
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with IκB family proteins, which consist of IκBα, IκBβ,
and IκBε. In response to the appropriate signals,
these three proteins are phosphorylated, polyubiquiti-
nated, and degraded though the ubiquitin-protea-
some pathway (Fig. 1), thereby freeing NF-κB to
translocate to the nucleus where it activates its target
genes.16
The phosphorylation event in this sequence is car-
ried out by a high molecular mass, multiprotein
kinase complex containing two subunits with kinase
activity (IKK1α and IKK2β) and NEMO (IKK3γ).
The human NEMO gene, located at Xq28, is a 23-kb
gene structured in nine exons and four alternative
non-coding first exons. A non-functional copy of the
NEMO gene, IKBKGP (also referred to as the
NEMO pseudogene), is located 31.6 kb distal to exon
10 (Fig. 2A). IKBKGP maps within a 35.7-kb dupli-
cated fragment that is oriented tail to tail with the
NEMO gene and contains exons 3-10, with 99.8% ho-
mology.18 The ~48-kDa NEMO protein is composed
of two coiled coil (CC1, CC2) domains, a leucine-
zipper (LZ) domain, a NEMO ubiquitin-binding
Kawai T et al.
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Table　1　Clinical and immune function associated with hypomorphic NEMO mutations in reported cases and Japanese cases
Functional or clinical category Modifi ed - Hanson et al.11 Japanese cases
Ectodermal dysplasia 40/52 ( 77%)  9/10 ( 90%)
Osteopetrosis  5/65 (  8%)  0/10 (  0%)
Lymphedema  5/65 (  8%)  1/10 ( 10%)
Autoimmune/infl ammatory disease 14/66 ( 23%)  5/10 ( 50%)
Dead 24/66 ( 36%)  2/10 ( 20%)
Infectious susceptibility 60/61 ( 98%) 10/10 (100%)
  Bacterial infection 45/52 ( 86%) 10/10 (100%)
  Mycobacterial infection 23/52 ( 44%)  4/10 ( 40%)
  Pneumocystis pneumonia  4/52 ( 21%)  0/10 (  0%)
  DNA-virus infection 11/52 ( 21%)  1/10 ( 10%)
  Meningitis 12/61 ( 21%)  1/10 ( 10%)
  Pneumonia 19/61 ( 31%)  3/10 ( 30%)
  Sepsis/bacteremia 20/61 ( 33%)  5/10 ( 50%)
  Abscess 18/61 ( 30%)  3/10 ( 30%)
Hypogammaglobulinemia 24/41 ( 59%) N.D.
Specifi c antibody defi ciency 18/28 ( 64%) N.D.
Impaired antibody response to polysaccharide 13/16 ( 94%)  3/3  (100%)
Impaired NK cell cytotoxicity 10/10 (100%) N.D.
(NUB) domain, and a zinc finger (ZF) domain (Fig.
2B).19 NEMO has no apparent catalytic activity but is
instead required in activation of the kinase complex
in response to extracellular (or intracellular) stimuli,
such as members of the TIR (TLR-ligands, IL-1β, and
IL-18), and TNFR (TNF-α, LTα1β2, and CD154) su-
perfamilies.5 The protein interacts with the IKK com-
plex through the N-terminal portion of its CC1. Upon
cytokine signalling, Lys-63-linked or linear ubiquitin
chains bind the NUB and ZF domains; the latter
bears a second ubiquitin-binding site. This interaction
with ubiquitin promotes the recruitment and oli-
gomerisation of NEMO, with the latter achieved by
the assembly of the CC2LZ portion of NEMO. After
inducing upstream signalling, CC2LZ converts to its
fully folded conformation and forms oligomers of
NEMO, which activate the IKK complex and lead to
the phosphorylation of IκB family proteins.19-22
Hypomorphic mutations of NEMO impair IκBα
phosphorylation and the sequential activation of
NF-κB, resulting in the variable clinical features of
EDA-ID. By contrast, amorphic mutations of NEMO
are lethal in males and result in incontinentia pig-
menti in females.23,24 The multiple functional do-
mains of NEMO may explain why NEMO mutations
are scattered throughout the NEMO gene as well as
the broad spectrum of clinical phenotypes.11
The IκBα protein, a member of the serine
threonine protein kinase family, contains phospho-
rylation sites at its N-terminal, ankyrin repeat do-
mains in its central portion, and, at its C-terminal, re-
peated peptidic sequence rich in proline, glutamic
acids, serine, and threonine (rPEST) domains (Fig.
2C).7 IκBα inhibits activation of the NF-κB complex
while phosphorylation of Ser32 and Ser36 in its phos-
phorylation domains triggers IκBα ubiquitination,
leading to degradation of the protein within the pro-
teasome and, in turn, the nuclear translocation of NF-
κB and subsequent activation of its target genes.
Hypermorphic mutations of IκBα impair its phos-
phorylation such that mutant IκBα molecules accu-
mulate in the cytoplasm, thereby inhibiting the nu-
clear translocation of NF-κB and target-gene activa-
tions.7 All of the reported IκBα mutations were
shown to cause abnormalities in the phosphorylation
site of IκBα, resulting in the abnormal accumulation
of the protein and therefore the retention of NF-κB in
the cytoplasm.
CLINICAL MANIFESTATIONS OF XL-EDA-ID
NF-κB is involved in many forms of signal transduc-
tion, including pathways involving interleukin 1 (IL-1)
family protein receptors, Toll-like receptor, vascular
endothelial growth factor receptor-3 (VEGFR-3), re-
ceptor activator of nuclear factor κB (RANK), the
ectodysplasin-A receptor, CD40, and the tumour ne-
crosis factor (TNF) receptor.16 Consequently, muta-
tions in NEMO cause abnormalities of these routes of
signal transduction, and thus the clinical features
documented in XL-EDA-ID patients. The clinical
manifestations of XL-EDA-ID described by Hanson et
al. and those of Japanese cases are shown in Table 1.
EDA
The development of cell types and tissues of ectoder-
mal origin, such as keratinocytes, hair follicles, and
sweat glands, is associated with the ectodysplasinec-
todysplasin receptor signalling pathway. Ectodyspla-
Manifestations and Mutations in EDA-ID
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sin, a member of the TNF family, is encoded by the
ED1 (formerly the EDA) gene. The ectodysplasin re-
ceptor is homologous to members of the TNF recep-
tor superfamily and is encoded by the DL [the
ortholog of the mouse downless gene (dl)] gene. Mu-
tations in ED1 are responsible for the X-linked reces-
sive type of EDA, and mutations in DL for the autoso-
mal recessive and autosomal-dominant types of the
disease. NF-κB activation is an essential step in the
ectodysplasinectodysplasin signalling pathway. Mu-
tations in NEMO or IκBα impair this pathway, result-
ing in the various manifestations of EDA in affected
patients.5
A clinical diagnosis of EDA is obtained when at
least two of the following seven characteristics are ob-
served: (1) decreased skin pigment, (2) periorbital
wrinkling and hyperpigmentation, (3) sparse to ab-
sent hair, (4) hypoplastic to absent sweat glands, (5)
hypodontia to anodontia with a tendency to delayed
eruption, resulting in a deficient alveolar ridge or
conically shaped anterior teeth, (6) low nasal bridge,
small nose with hypoplastic alae nasi, and (7) full
forehead with prominent supraorbital ridges.11
Interestingly, although EDA is one of the charac-
teristic signs of EDA-ID, it is not always apparent dur-
ing early infancy and is totally absent in some pa-
tients (Table 1). In these cases, recognition of the
typical immunological abnormalities should be fol-
lowed by genetic analysis of the NEMO and IkBα
genes.
OSTEOPETROSIS AND VASCULAR ANOMALIES
Osteopetrosis and vascular anomalies are observed in
patients with severe phenotypes of XL-EDA-ID. This
form of the disease is called EDA-ID with osteopetro-
sis and lymphedema (OL-EDA-ID). Most of these pa-
tients present with failure to thrive and refractory in-
fections, including Pneumocystis pneumonia, necessi-
tating hematopoietic stem cell transplantation
(HSCT) to avoid premature death from related com-
plications.5,11,25
In various animal models, RANKL- and TNF-
induced NF-κB signalling were shown to influence
osteoclastogenesis in the bone marrow. In humans
with XL-EDA-ID, the characteristic osteopetrosis can
be explained by the inhibition of osteoclastogenesis
due to impaired RALKL-induced signalling and sus-
ceptibility to TNF-α-induced apoptosis of osteoclast
precursors, as a consequence of NEMO muta-
tions.5,26
Mutations in VEGFR-3 were shown to cause pri-
mary lymphedema due to the related vascular anoma-
lies and the fact that VEGFR-3 signalling induces NF-
κB activation. The lymphedema observed in OL-EDA-
ID may reflect severe dysfunctional NF-κB activation,
likewise caused by NEMO mutations.5
SUSCEPTIBILITY TO BACTERIAL AND VIRAL
INFECTIONS
Most XL-EDA-ID patients present with increased sus-
ceptibility to infections, particularly those of bacterial
origin. Although hypogammaglobulinemia occurs in
only 59% of the patients, in most of them the impair-
ment consists of the failure to mount a specific anti-
body response to pneumococcal polysaccharides, re-
sulting in susceptibility to pyogenic bacteria includ-
ing Streptococcus pneumoniae, Haemophilus influenza,
and Staphylococcus aureus.11
Also in EDA-ID, the observed deficiencies in innate
immunity, i.e., the increased susceptibility to bacte-
rial and viral infections, are caused by the impaired
cellular responses to various stimuli, including TNF-
α, IL-1β, IL-18, and lipopolysaccharides.5 Moreover,
CD40-mediated signals are partially impaired in both
dendritic cells and B cells, which likewise leads to an
impaired antibody response.
SUSCEPTIBILITY TO MYCOBACTERIA
Some XL-EDA-ID patients are particularly vulnerable
to mycobacterial infections, which are one of the
most serious complications associated with the dis-
ease. Infections with the various mycobacterial spe-
cies, among which Mycobacterium avium intracellu-
lare is the most commonly reported,11 manifest as
cellulitis, osteomyelitis, lymphadenitis, pneumonia,
and disseminated diseases. In Japanese cases of XL-
EDA-ID, two of four patients with mycobacteria infec-
tion were positive for bacillus Calmette-Guerin
(BCG). Therefore, the treating physician should
make sure that he or she is appropriately vaccinated.
The increased frequency of mycobacterial infec-
tions in XL-EDA-ID patients can be ascribed to an in-
trinsic defect of T cell-dependent IL-12 production by
monocytes, resulting in defective IFN-γ secretion by
T cells. IL-12 production is also impaired as the result
of a defect in NEMO-mediated CD40 signalling by
monocytes and dendritic cells.5,27,28
DEFECTIVE NK CELL CYTOTOXICITY
XL-EDA-ID patients have impaired NK cell cytotoxic-
ity although the number of NK cells in the peripheral
blood is normal. In fact, the identification of an NK
cell defect may be considered as diagnostic of XL-
EDA-ID in the presence of the corresponding clinical
features.11,29 This abnormality was partially reversed
by the in vitro addition of IL-2. Signalling by NKp30 is
associated with NF-κB activation in the canonical
pathway. NKp30 is one of the natural cytotoxicity re-
ceptors, which are major receptors expressed almost
exclusively on human NK cells. The defects in NK
cell cytotoxicity in patients with NEMO mutations
can be explained by the impaired NF-κB activity in
the canonical pathway, which is induced after the
ligation of specific activating receptors, including
NKp30.30 Interestingly, defective NK cell cytotoxicity
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has not been found in AL-EDA-ID patients.7
Finally, defective NK cell cytotoxicity may also ex-
plain the increased susceptibility of XL-EDA-ID pa-
tients to infections with the herpes group of viruses.
INFLAMMATORY DISEASES
Inflammatory disorders and autoimmunity are often
observed in XL-EDA-ID, with inflammatory colitis
(called NEMO colitis) accounting for 25% of the cases
in these patients.11 NEMO colitis, which usually oc-
curs early in childhood, causes intractable diarrhoea
and failure to thrive. Histological examination shows
active colitis with abundant neutrophil infiltration.31-33
In searching for the mechanisms underlying the
association of NEMO colitis with XL-EDA-ID, Nanci
et al. produced a mouse model based on a conditional
NEMO knockout in the gut epithelium. NEMO-
deficient epithelial cells were shown to be sensitive to
TNF-α-induced apoptosis and accounted for the se-
vere chronic intestinal inflammation. Accordingly, the
authors suggested that the impaired NF-κB signalling
in EDA-ID resulted in TNF-α induced apoptosis and
subsequent inflammatory diseases.34
PROGNOSIS
According to the database of XL-EDA-ID, the mean
age at death is 6.4 years. In more recent cases, death
has occurred even earlier, although this is probably
an artifactual finding reflecting earlier recognition of
the disease based on its improved diagnosis.11
DIAGNOSIS OF XL-EDA-ID
In the many XL-EDA-ID patients with normal immu-
nological findings, early diagnosis of the disorder is
particularly difficult.1-4,8 However, since EDA is char-
acteristic and diagnostically useful in EDA-ID pa-
tients,4 recognition by the physician of its signs in an
infant warrants a genetic analysis. Nevertheless, EDA
is not a consistent finding and even if the characteris-
tic signs are absent, EDA-ID should not be ex-
cluded.35 For example, if the patient suffers from re-
current bacterial infections or environmental myco-
bacterial infections, XL-EDA-ID should be included in
the differential diagnosis. In this setting, the analysis
of NK cell cytotoxicity could be helpful.29
NEMO mutations are scattered throughout the
NEMO gene (Fig. 1C), which accounts for the nu-
merous clinical phenotypes of EDA-ID. Indeed,
genotype-phenotype correlations have been shown in
recent studies. Thus, genotyping might, at least to
some extent, serve to predict the EDA-ID phenotype
in affected patients.
The presence of the NEMO pseudogene makes it
difficult to perform genetic analysis using genomic
DNA with Sanger sequencing. Instead, NEMO muta-
tions should be identified by sequencing analysis of
NEMO cDNA. Large deletion or duplication muta-
tions in the NEMO gene have been detected in some
cases of XL-EDA-ID36 and in the majority of patients
with incontinentia pigmenti.23 Therefore, additional
molecular methods, including Southern blotting
analysis, and detailed PCR analyses can provide im-
portant diagnostic information.
As noted above, the coding sequence of NEMO
cDNA extends from exon 2 to exon 10. Lymphocytes
express NEMO transcripts comprising exons 1A, 1B,
or 1C spliced to exon 2, with exon1B transcripts mak-
ing up the majority of the three isoforms. In a case re-
port of a NEMO deficiency, a mutation at position +1
of the donor splice site of exon 1B resulted in aber-
rant NEMO mRNA and the reduced expression of a
normal NEMO protein.37 Therefore, genomic se-
quencing of all ten NEMO exons, i.e., including exon
1, is necessary in the genetic diagnosis of XL-EDA-
ID.
Despite ample genetic knowledge of the defects in
XL-EDA-ID, the presence of somatic mosaicism in
these patients poses a diagnostic challenge. Although
only three cases of XL-EDA-ID involving somatic mo-
saicism have been published in the literature,33,36,38
our recent study determined a much higher fre-
quency.39 Among the patients analysed by our group,
somatic mosaicism was observed predominantly in T
cells, which suggested that NEMO is critical to T cell
proliferation. While the clinical impacts of somatic
mosaicism in XL-EDA-ID have not been demon-
strated, the presence of this form of the disease calls
for care in its genetic diagnosis. Flow cytometric
analysis of the NEMO protein is diagnostically useful
for some, but not all of the NEMO mutations occur-
ring in somatic mosaicism.36,38
CLINICAL MANIFESTATIONS OF AD-EDA-ID
Mutations of IκBα cause signal transduction abnor-
malities that are associated with NF-κB activation, re-
sulting in various clinical manifestations, analogous to
mutations in NEMO.7
In AD-EDA-ID, four mutations in the IκBα gene
have been reported, p.Ser32Ile7,12 and three non-
sense mutations p. Gln 9 X, p. Trp 11 X, and
p.Glu14X.13-15 Among the AD-EDA-ID patients re-
ported in the literature, EDA was a consistent finding,
except in patients with IκBα p.Ser32Ile mosaicism
(Table 2). This latter group suffered from severe re-
current bacterial infections, Pneumocystis jiroveci in-
fection, and cutaneous candidiasis. Hypogam-
maglobulinemia with no specific antibodies, reduced
TCRγδ T cells, and low T cell proliferation in re-
sponse to anti-CD3 were determined as well. Further-
more, although a deficiency in NK cell cytotoxicity is
seen in most NEMO-deficient patients, it was not de-
tected in patients with the p.Ser32Ile mutation.7,12
A pediatric patient with somatic mosaicism involv-
ing the p.Ser32Ile IκBα mutation presented with juve-
nile idiopathic arthritis and was subsequently treated
with steroid administration for 10 years during child-
hood. As an adult, he presented with tentative
Manifestations and Mutations in EDA-ID
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Table　2　Clinical symptoms and immune functions associated with the various IκBα
Mutations of IκBα p.32Ile p.32Ile mosaicism Gln9X Trp11X Glu14X
EDA + - + + +
Failure to thrive + - + - +
Bacterial infection Severe Episodic S.typhimurium infection Severe
Recurrent
pneumonia Severe
Pneumocystic 
jiroveci infection + - - - +
Cutaneous
candida infection + - - - +
Autoimmune or 
infl ammatory 
disease
-
Systemic JIA
(in childhood)
RF(+) oligoarthritis
(in adulthood)
Infl ammatory 
bowel disease - -
Treatment
IVIG
HSCT 
Steroid
Non-steroidal-anti-
infl ammatory drugs
IVIG
HSCT
(scheduled)
Healthy with IVIG
IVIG
HSCT
(died due to sepsis)
Gammaglobulin 
abnormality
Hypogamma-
globulinemia - Increased IgA
Increased IgA, 
decreased IgM -
Specifi c antibody 
defi ciency + - n.d. + n.d.
Lymphocytosis + - + - +
Abnormal lympho-
cyte proliferation 
Normal (PHA)
Reduced
 (CD3, candi-
din, tetanus)
Mildly reduced  
(CD3,PHA)
Reduced
(PHA, Con-A)
Normal
(PHA, CD3, CD3/
CD28,  tetanus,
diphtheria)
Normal
(PHA,PWM, 
Con-A, tetanus)
TCRγδ Decreased Normal n.d. n.d. Decreased
NK cell abnormali-
ties
Normal NK cell 
activity n.d. n.d.
Normal percent-
age of NK cells Reduced NK cells
Impaired TLR 
response + + + +
rheumatoid-factor-positive oligoarthritis. An episodic
Salmonella typhimurium infection was effectively
treated with antibiotics and the patient has since been
healthy.12 This case suggests that somatic mosaicism
in the p.Ser32Ile mutation accounts for the autoim-
mune disorders seen in some EDA-ID patients.
The patients with the three nonsense mutations
(p.Trp11X, p.Gln9X, and p.Glu14X) had a normal IgG
levels. The patient with the p.Glu14X mutation pre-
sented with failure to thrive since early childhood and
suffered from recurrent bacteremia and Pneumocystis
jiroveci infections. The p.Glu14X mutation causes a
downstream re-initiation of translation of IκBα
mRNA. The resulting N-terminally truncated protein
lacks both serine phosphorylation sites (Ser32 and
Ser36) and inhibits NF-κB activation by working as a
dominant negative repressor in lymphocytes and
monocytes.14 The patient with the p.Gln9X mutation
had suffered from recurrent viral and bacterial infec-
tions beginning in early childhood and later from in-
flammatory bowel disease.15 The patient with
p.Trp11X mutation presented with recurrent pneumo-
nia and bronchiectasis but no history of bacteremia
or mycobacterial infections. She had been healthy fol-
lowing the initiation of immunoglobulin infusion ther-
apy, at the age of 10 years.13 Similar to p.Glu14X,
p.Trp11X and p.Gln9X manifest as downstream re-
initiation mutations. However, why the three non-
sense mutations give rise to three distinct clinical pic-
tures remains to be explored.
DIAGNOSIS OF AD-EDA-ID
As noted above, EDA is a diagnostically helpful mani-
festation of AD-EDA-ID because it is seen in all of
these patients, except in those with somatic mosa-
icism. Recurrent severe infections with various patho-
gens are common, including bacteria, virus, fungi,
and, in young infants, Pneumocystis jiroveci.7,12-15 Al-
though the immune dysfunctions seen in AL-EDA-ID
are more severe than those typical of XL-EDA-ID,
they are not diagnostically conclusive and cannot be
used to distinguish between XL-EDA-ID and AD-
Kawai T et al.
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Table　3　Summary of reported cases of EDA-ID in which the patient underwent HSCT
Case Mutation HLA match Source Conditioning Outcome Refer-ences
1
NEMO 
c.1167_1168
insC
UD 2/6 matched
Disparate at HLA-A by 
serology, disparate at both 
HLA-A and both HLA-DR by 
DNA typing
CB
Fludarabine 150 mg/m2
Melphalan 140 mg/m2
rATG  12.5 mg/kg
Alive 31
2
(First HSCT)
NEMO 
c.1167_1168
insC
Matched sibling PSC
Fludarabine 6 mg/kg/day
Busulfan target 4000 μM/min 
i.v. × 2 days
rATG  8 mg/kg
Graft failure
32
2
(Second HSCT) Same donor PSC
Fludarabine 5 mg/kg/day
Melphalan 3.5 mg/kg
Alemtuzumab 30 mg/kg
Alive
Rash, diarrhea
3
NEMO 
c.1167_1168
insC
UD 7/10 matched
Disparate at HLA-B and 
both HLA-C
CB
Busulfan target 900-1300 μM/
min i.v. 6 h × 16 doses
Cyclophosphamide 200 mg/kg
eATG 90 mg/kg
Alive 42
4 NEMOc.1259A>C UD matched BM
Busulfan 20 mg/kg
Cyclophosphamide 200 mg/kg
rATG 5 mg/kg
Died at day +6 
from veno-occlu-
sive disease
25
5
(First HSCT)
NEMO
c.768 + 5G>A
UD matched BM
Busulfan 1 mg/kg i.v. 6 h × 16 
doses
Cyclophosphamide 200 mg/kg
rATG 9 mg/kg
Graft failure
32
5
(Second HSCT) Same donor PSC Fludarabine 160 mg/m
2
Died at day +314 
due to para-infl u-
enza type III virus 
infection
6 NEMOc.458T>G Matched sibling BM
Busulfan target 900-1300 μM/
min i.v. 6 h × 16 doses
Cyclophosphamide 200 mg/kg
Alive
Continued colitis
40
7 NEMOc.931C>G UD Matched BM
Fludarabine 150 mg/m2
Melphalan 140 mg/m2
rATG  5 mg/kg
Alive 38
8
NEMO
duplication of 
exon 4-5
UD 5/8 locus matched
Disparate at HLA-B by 
serology
Disparate at HLA-A, B, and 
C by DNA typing
CB
Fludarabine 150 mg/m2
Melphalan 140 mg/m2
rATG 12.5 mg/kg
T-cell graft failure
Died at day +60 
due to sepsis
39
9
(First HSCT)
IκBα STOP 
codon Glu14
UD 8/10 locus matched
Disparate at HLA-B and C
CB
Fludarabine 5 mg/kg
Cyclophosphamide 200 mg/kg
rATG  9 mg/kg
Graft failure
32
9
(Second HSCT)
UD 7/8 locus matched
Disparate at HLA-A
CB
Busulfan 1.1 mg/kg i.v. 6 h × 
16 doses
Cyclophosphamide 200 mg/kg
Alemtuzumab 36 mg/kg
Graft failure
Died from sepsis 
due to Pseudo-
monas aeruginisa
10
IκBα mis-
sense muta-
tion at Ser 32
Maternal haploidentical BM
Busulfan 20 mg/kg
Cyclophosphamide 200 mg/kg
Alive 43
Abbreviations: rATG, rabbit antithymocyte globulin; eATG, equine antithymocyte globulin; UD, unrelated donor; CB, cord blood; PSC, pe-
ripheral stem cell; BM, bone marrow.
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EDA-ID nor do they obviate the need for a genomic
diagnosis of NEMO and IκBα in males with sus-
pected EDA-ID.
TREATMENT
For most XL-EDA-ID patients and for all those with
AD-EDA-ID, treatment should consist of intravenous
or subcutaneous immunoglobulin administration be-
cause of the impaired antibody response to polysac-
charides and the susceptibility to pyogenic bacterial
infection seen in the two conditions, despite the pres-
ence of normal levels of specific antibodies against
other pathogens.2 In EDA-ID patients with suspected
infections, early empirical intravenous antibiotic ad-
ministration is essential as the disease also results in
an inability to increase plasma C-reactive protein
(CRP) concentrations and to mount a fever as part of
the initial inflammatory response, due to the impair-
ment of Toll-like receptor signalling.
Candida albicans and Pneumocystis jirovecii infec-
tions are seen in some XL-EDA-ID patients and in
nearly all AD-EDA-ID patients.5,7,14,25 In such cases,
the early and adequate administration of antibiotic
prophylaxis, with cotrimoxazole and anti-fungal
drugs, is strongly recommended.
Chronic atypical mycobacterial infections are also
frequent in XL-EDA-ID and they are associated with a
poor prognosis.11 These infections progress insidi-
ously and are almost inevitably disseminated at the
time of disease diagnosis. In the three Japanese pa-
tients with XL-EDA-ID and atypical mycobacterial in-
fections, only one sign or symptom, i.e., lymphadeno-
pathy (BCG-positive), failure to thrive (Mycobacte-
rium szulgai infection), and intractable diarrhoea (ba-
cillus Calmette-Guerin) led, respectively, to the cor-
rect diagnosis.36,38 However, by that time, the myco-
bacterial infections had already disseminated, thus
highlighting the importance of their periodic surveil-
lance in EDA-ID patients. It should be noted that al-
though most AD-EDA-ID patients show a severe im-
munodeficiency, atypical mycobacterial infections
have not been reported, perhaps due to the early
mortality or because HSCT was performed in early
childhood. NEMO colitis often has a complicated
course in XL-EDA-ID such that the quality of life of
these patients is reduced considerably. Corticoster-
oids, but not antimicrobial agents have been shown
to be effective in this setting.40,41 In a case report, in-
flammatory colitis in an XL-EDA-ID patient was suc-
cessfully treated with anti-TNFα antibody administra-
tion.33 Although this approach is likely to increase the
risk of mycobacterium infection, it may still be a
therapeutic option in patients with NEMO colitis.
Two patients with AD-EDA-ID and combined im-
munodeficiency and eight patients with XL-EDA-ID of
severe clinical phenotype underwent HSCT (Table
3).25,32,38-40,42,43 In five of the patients with XL-EDA-ID
and in one with AD-EDA-ID, both the immunodefi-
ciency and long-term survival improved, whereas in
two patients with XL-EDA-ID, the disease remained
unmodified. Three XL-EDA-ID patients and one with
AD-EDA-ID died after HSCT, one from veno-
occlusive disease, one from para-influenza virus type
III, one from septic shock, and one other from bacte-
rial sepsis caused by a resistant strain of Pseudo-
monas aeruginosa. Three XL-EDA-ID patients and
one AD-EDA-ID patient experienced graft failure.
These cases suggest that EDA-ID patients have in-
trinsic difficulties with successful engraftment32 such
that novel therapeutic approaches to this heterogene-
ous genetic disorder are needed.
CONCLUSIONS
Patients with EDA-ID present with various patholo-
gies, including a high susceptibility to infections, the
extent of which depends partially on the underlying
genotype of the disease. In XL-EDA-ID patients,
NEMO mutations scattered across the entire NEMO
gene have been identified. These no doubt explain
the broad spectrum of clinical manifestations that are
typical for XL-EDA-ID. Accordingly, a genetic analy-
sis is critical for its early diagnosis and appropriate
treatment.
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